Lifecore Biomedical, Inc. LFCR Derivative Liability, Noncurrent

Derivative Liability, Noncurrent at other companies

Halozyme TherapeuticsHALO

——

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Market cap$196.92M-35.4%

Enterprise value$333.06M+8.3%

P/S1.6×+0.5×

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Lifecore Biomedical, Inc.'s derivative liability, noncurrent?: Lifecore Biomedical, Inc. (LFCR) reported derivative liability, noncurrent of $29.72M in Q1 2026.
How has Lifecore Biomedical, Inc.'s derivative liability, noncurrent changed year-over-year?: Lifecore Biomedical, Inc.'s derivative liability, noncurrent increased by 18.9% year-over-year, from $24.99M to $29.72M.